Canterbury DHB


Supportive Measures

The following are recommended:

The following are recommended for fludarabine-based treatment:

In This Section



Blood products



Patients with CLL should receive annual influenza vaccinations. In addition pneumoccocal vaccination is also advised. Although antibody formation by CLL patients may be sub-optimal, pneumonia is a common cause of death in this disease.


See Nausea and Vomiting.

Blood products

Blood and platelet transfusions will be given at the discretion of the treating physician. Patients treated with fludarabine or fludarabine plus cyclophosphamide must receive irradiated blood products to prevent the rare occurrence of transfusion associated graft versus host disease. This should continue for at least 6 months after the end of the fludarabine therapy.


This may be indicated in non-responding patients who remain with a markedly enlarged spleen after an adequate trial of primary therapy. For further information, see Prevention of Infection Pre-splenectomy and in Splenic Atrophy in the Infection including Prophylaxis section.

About this Canterbury DHB document (5530):

Document Owner:

Blake Hsu (see Who's Who)

Last Reviewed:

September 2018

Next Review:

September 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5530